Printer Friendly

AGOURON PHARMACEUTICALS OFFERS SYNOPSIS OF REMARKS AT CRUTTENDEN SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE

 NEWPORT BEACH, Calif., Feb. 18 /PRNewswire/ -- The following is a summary of a presentation made by San Diego-based Agouron Pharmaceuticals Inc. (NASDAQ-NMS: AGPH) today at the Cruttenden Southern California Growth Stock Conference:
 In a presentation to be made today at the Cruttenden Southern California Growth Stock Conference, Peter Johnson, president of Agouron Pharmaceuticals Inc. will give an overview of the company's business strategy and product pipeline.
 The mission of Agouron Pharmaceuticals is the discovery, development and commercialization of innovative drugs for treatment of cancer, viral diseases including AIDS, and such major inflammatory diseases as arthritis. What distinguishes Agouron apart is its method of finding these new products. Using a fusion of technologies described as "Protein Structure-Based Drug Design," Agouron designs novel therapeutic drug molecules atom-by-atom to produce predetermined therapeutic effects.
 In the most advanced of 10 different R&D programs, Agouron scientists have successfully applied this technology to a widely pursued target for new anticancer drugs and the company has now moved five products into development. Three of these are now in clinical trials either in the United States or Europe. The first of these products, designated AG-337, is the subject of a Phase I study in cancer patients at a large medical center in England. A second anticancer drug, designated AG-331, has recently become the subject of a Phase I clinical study at the University of Southern California. A third drug, AG-85, is being evaluated as a topical anti-psoriatic agent in two concurrent studies being conducted at the University of California, Irvine, and the Skin Research Foundation of California in Santa Monica.
 Agouron has conducted its lead product development program on an independent, self-funded basis as a result of which it has generated significant operating losses. The result of this self-investment is that the company owns all worldwide commercial rights to these drug products. The company's strategy is to retain these commercial rights as the basis for building an independent integrated pharmaceutical firm engaged directly in development, manufacturing and marketing of its own patented products for oncologists and certain other physician groups.
 At the same time Agouron is applying its drug design technology to new therapeutic targets in cooperation with major corporate partners. With Eli Lilly, Agouron is engaged in development of anti- HIV drugs for treatment of AIDS under an agreement which takes advantage of Lilly's strengths in development and marketing of products for infectious diseases, but which gives Agouron up to half of profits ultimately generated from the sale of jointly developed products. With Schering-Plough, Agouron is pursuing discovery of a new class of anti-cancer drugs under arrangements which provide Agouron an option to co-market resulting products. A recently concluded agreement links the efforts of Agouron and Japan Tobacco in the discovery and commercialization of novel drugs in the field of immunology and provides for the payment of more than $30 million to Agouron over the next three to four years.
 -0- 2/18/93
 /CONTACT: Donna Nichols of Agouron Pharmaceuticals, 619-622-3000/
 (AGPH)


CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU:

JL-JB -- LA010 -- 7695 02/18/93 08:51 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1993
Words:514
Previous Article:MATTHEWS STUDIO EQUIPMENT GROUP OFFERS SYNOPSIS OF REMARKS AT CRUTTENDEN SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE
Next Article:VETERINARY CENTERS OF AMERICA OFFERS SYNOPSIS OF REMARKS AT CRUTTENDEN SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE
Topics:


Related Articles
AGOURON NAMES VICE PRESIDENT AND GENERAL COUNSEL
SPI PHARMACEUTICALS EXPECTS 1991 SALES TO REACH $360 MILLION
/C L A R I F I C A T I O N -- SPI PHARMACEUTICALS/
AGOURON PHARMACEUTICALS NAMES FORMER EXECUTIVE VICE PRESIDENT OF MARION LABORATORIES TO BOARD
FDA AUTHORIZES CLINICAL TESTING OF SECOND AGOURON ANTI-TUMOR DRUG
AGOURON AND SYNTEX TO COLLABORATE IN ARTHRITIS AND CANCER DRUG DISCOVERY
AGOURON PHARMACEUTICALS EXPANDS CLINICAL TESTING OF SECOND CANCER DRUG INTO UNITED STATES
AGOURON PHARMACEUTICALS INC. PRESENTS AT CRUTTENDEN
AGOURON PHARMACEUTICALS TO PRESENT AT HAMBRECHT & QUIST HEALTH CARE CONFERENCE; AGOURON PHARMACEUTICALS REPORTS R&D PROGRESS
ALLIANCE PHARMACEUTICAL CORP. HIGHLIGHTS CLINICAL PROGRESS; PARTNERSHIP ACTIVITIES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters